Core Viewpoint - The completion of the "R&D Center Construction Project" and "Information System Upgrade Project" marks a significant milestone for the company, showcasing its strong management capabilities and efficient use of funds [2] Group 1: Project Completion - The two projects have achieved a usable status and have officially completed their objectives [2] - A total of 14.8945 million yuan in surplus funds was generated, primarily due to cost control during project implementation, flexible use of self-owned funds, and interest from idle funds [2] Group 2: Financial Management - The company demonstrated effective resource allocation in line with technological trends, achieving efficient fund utilization without affecting project timelines [2] - The surplus funds reflect the company's robust operational management capabilities [2] Group 3: Strategic Focus - The completion of these projects signifies a key step in enhancing the company's R&D capabilities and digital transformation [2] - Following the project completion, the company will further concentrate on upgrading its core business and strengthening its R&D and digital advantages, injecting new momentum into industry development and investor returns [2]

Core Viewpoint - The company plans to establish a research and development subsidiary in Wuhan to enhance its ability to attract and integrate top scientific talent and technical experts in the Central China region, accelerating the transformation and application of research results [1] Group 1 - The subsidiary, named EVE Power, has received approval from the company's board of directors and does not require shareholder approval [1] - The establishment of the subsidiary does not constitute a major asset restructuring or related party transaction [1]

Group 1: Acquisition and Product Development - The acquired asset group is expected to support a product sales volume of approximately 4 million units this year, with sufficient capacity from the production partner, Xuchang Future [1] - The Multi-Micro (III) product is currently under technical review and is expected to be approved next year, targeting children weighing ≥15kg and adult patients [1] - A one-time payment of 6 million yuan will be made upon the approval and change of the marketing authorization holder for Multi-Micro (III) [2] Group 2: Health Products and Market Strategy - The company's health products are in the R&D optimization and commercialization phase, with a planned launch next year, depending on R&D progress and sales channel development [2] - The health products will primarily utilize online sales, separate from the existing pharmaceutical sales team, leveraging the company's unique raw material advantages [2] Group 3: Traditional Chinese Medicine (TCM) Business Stability - The TCM decoction pieces business is stable, with a strong brand presence established in Zhejiang province, particularly in Hangzhou and Huzhou [2] - The impact of centralized procurement on the TCM formula granules business is limited, as the company primarily operates within the province [2] Group 4: Fundraising and Investment Projects - The planned fundraising through convertible bonds aims to raise approximately 1 billion yuan, focusing on core capacity upgrades and R&D enhancements [2] - About 1 billion yuan is allocated for the construction of an intelligent TCM health factory, with an estimated construction period of 2-3 years [2]

Core Viewpoint - The company plans to establish a branch and research institute in Xi'an to enhance its R&D capabilities and expand its market influence [1] Group 1 - The establishment of the Xi'an Research Institute aims to strengthen the company's technological R&D capabilities [1] - The initiative is intended to assist the company in developing new products and exploring new markets [1] - The move is expected to significantly improve the company's independent R&D capabilities [1]